Symbols / PMVP Stock $1.12 -5.88% PMV Pharmaceuticals, Inc.

Healthcare • Biotechnology • United States • NMS
PMVP (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. David H. Mack Ph.D.
Exch · Country NMS · United States
Market Cap 59.73M
Enterprise Value -33.52M
Income -78.34M
Sales —
FCF (ttm) -47.07M
Book/sh 1.65
Cash/sh 1.75
Employees 54
Insider 10d —
IPO Sep 25, 2020
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -1.02
PEG —
P/S —
P/B 0.68
P/C —
EV/EBITDA 0.40
EV/Sales —
Quick Ratio 10.88
Current Ratio 11.14
Debt/Eq 0.33
LT Debt/Eq —
EPS (ttm) -1.48
EPS next Y -1.09
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-13
Earnings (prior) 2026-05-12
ROA -39.14%
ROE -63.16%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 53.33M
Shs Float 43.14M
Insider Own 3.35%
Instit Own 69.52%
Short Float 5.98%
Short Ratio 7.28
Short Interest 3.08M
52W High 1.88
vs 52W High -40.43%
52W Low 0.91
vs 52W Low 23.08%
Beta —
Impl. Vol. 3.38%
Rel Volume 0.74
Avg Volume 427.48K
Volume 314.64K
Target (mean) $4.33
Tgt Median $4.00
Tgt Low $4.00
Tgt High $5.00
# Analysts 3
Recom None
Prev Close $1.19
Price $1.12
Change -5.88%
About

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Princeton, New Jersey.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$4.33
Mean price target
2. Current target
$1.12
Latest analyst target
3. DCF / Fair value
$-15.89
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.12
Low
$4.00
High
$5.00
Mean
$4.33

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-13 main Oppenheimer Outperform → Outperform $5
2025-03-20 reit HC Wainwright & Co. Buy → Buy $5
2024-08-20 reit HC Wainwright & Co. Buy → Buy $5
2024-05-30 reit HC Wainwright & Co. Buy → Buy $5
2024-05-14 reit HC Wainwright & Co. Buy → Buy $5
2024-05-13 init Craig-Hallum — → Buy $6
2024-04-12 init Jefferies — → Buy $5
2024-03-07 reit HC Wainwright & Co. Buy → Buy $5
2023-12-27 init Ladenburg Thalmann — → Buy $7
2023-10-16 main HC Wainwright & Co. Buy → Buy $5
2023-08-11 main HC Wainwright & Co. Buy → Buy $29
2023-05-17 reit HC Wainwright & Co. Buy → Buy $35
2023-05-11 reit Oppenheimer Outperform → Outperform $15
2023-03-20 main HC Wainwright & Co. — → Buy $35
2023-03-02 main Oppenheimer — → Outperform $15
2022-11-17 main HC Wainwright & Co. — → Buy $36
2022-06-09 main Oppenheimer — → Outperform $33
2022-05-24 main Goldman Sachs — → Buy $25
2022-03-02 up Oppenheimer Perform → Outperform —
2021-09-22 up Goldman Sachs Neutral → Buy $43
News
RSS: Latest PMVP news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-10-27 MACK DAVID HENRY Chief Executive Officer — 220,643 $1.37 $302,281
2025-10-23 ORBIMED ADVISORS, L.L.C. Beneficial Owner of more than 10% of a Class of Security — 1,000,000 $1.52 $1,520,000
2025-09-10 ORBIMED ADVISORS, L.L.C. Beneficial Owner of more than 10% of a Class of Security — 500,000 $1.27 $635,000
2025-07-01 MACK DAVID HENRY Chief Executive Officer — 58,411 $1.06 $62,179
2025-07-01 TICKTIN ROBERT Chief Operating Officer — 23,151 $1.06 $24,651
2025-07-01 JALOTA DEEPIKA Officer — 33,065 $1.06 $35,198
2025-07-01 CARULLI MICHAEL Chief Financial Officer — 28,249 $1.06 $30,077
2025-01-03 MACK DAVID HENRY Chief Executive Officer — 109,459 $0.53 $58,013
2024-09-11 JALOTA DEEPIKA Officer — 7,218 $1.50 $10,853
2024-09-11 CARULLI MICHAEL Chief Financial Officer — 2,891 $1.50 $4,347
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
86.21
+0.89%
85.45
+6.63%
80.13
+4.01%
77.04
Research And Development
69.88
+19.39%
58.53
+4.73%
55.88
+7.50%
51.99
Selling General And Administration
16.33
-39.34%
26.92
+11.03%
24.25
-3.21%
25.05
General And Administrative Expense
16.33
-39.34%
26.92
+11.03%
24.25
-3.21%
25.05
Other Gand A
16.33
-39.34%
26.92
+11.03%
24.25
-3.21%
25.05
Total Expenses
86.21
+0.89%
85.45
+6.63%
80.13
+4.01%
77.04
Operating Income
-86.21
-0.89%
-85.45
-6.63%
-80.13
-4.01%
-77.04
Total Operating Income As Reported
-86.21
-0.89%
-85.45
-6.63%
-80.13
-4.01%
-77.04
EBITDA
-86.07
-2.10%
-84.30
-6.88%
-78.88
-2.80%
-76.72
Normalized EBITDA
-86.07
-2.10%
-84.30
-6.88%
-78.88
-2.80%
-76.72
Reconciled Depreciation
0.13
-88.37%
1.14
-8.99%
1.26
+299.05%
0.32
EBIT
-86.21
-0.89%
-85.45
-6.63%
-80.13
-4.01%
-77.04
Net Income
-77.74
-32.42%
-58.71
+14.87%
-68.96
+5.94%
-73.32
Pretax Income
-79.91
-6.82%
-74.81
-8.48%
-68.96
+5.96%
-73.33
Net Non Operating Interest Income Expense
6.34
-40.53%
10.65
-4.62%
11.17
+208.00%
3.63
Net Interest Income
6.34
-40.53%
10.65
-4.62%
11.17
+208.00%
3.63
Interest Income Non Operating
6.34
-40.53%
10.65
-4.62%
11.17
+208.00%
3.63
Interest Income
6.34
-40.53%
10.65
-4.62%
11.17
+208.00%
3.63
Other Income Expense
-0.04
-181.25%
-0.02
-633.33%
0.00
-96.55%
0.09
Other Non Operating Income Expenses
-0.04
-181.25%
-0.02
-633.33%
0.00
-96.55%
0.09
Tax Provision
-2.17
+86.51%
-16.10
-805100.00%
0.00
+122.22%
-0.01
Tax Rate For Calcs
0.00
-85.71%
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-77.74
-32.42%
-58.71
+14.87%
-68.96
+5.94%
-73.32
Net Income From Continuing Operation Net Minority Interest
-77.74
-32.42%
-58.71
+14.87%
-68.96
+5.94%
-73.32
Net Income From Continuing And Discontinued Operation
-77.74
-32.42%
-58.71
+14.87%
-68.96
+5.94%
-73.32
Net Income Continuous Operations
-77.74
-32.42%
-58.71
+14.87%
-68.96
+5.94%
-73.32
Normalized Income
-77.74
-32.42%
-58.71
+14.87%
-68.96
+5.94%
-73.32
Net Income Common Stockholders
-77.74
-32.42%
-58.71
+14.87%
-68.96
+5.94%
-73.32
Diluted EPS
-1.48
-29.82%
-1.14
+20.83%
-1.44
+10.56%
-1.61
Basic EPS
-1.48
-29.82%
-1.14
+20.83%
-1.44
+10.56%
-1.61
Basic Average Shares
52.54
+1.87%
51.58
+7.42%
48.01
+5.31%
45.59
Diluted Average Shares
52.54
+1.87%
51.58
+7.42%
48.01
+5.31%
45.59
Diluted NI Availto Com Stockholders
-77.74
-32.42%
-58.71
+14.87%
-68.96
+5.94%
-73.32
Line Item Trend 2023-12-31
Total Assets
252.15
Current Assets
207.41
Cash Cash Equivalents And Short Term Investments
203.06
Cash And Cash Equivalents
37.71
Other Short Term Investments
165.35
Prepaid Assets
—
Restricted Cash
0.82
Other Current Assets
3.53
Total Non Current Assets
44.74
Net PPE
19.05
Gross PPE
22.32
Accumulated Depreciation
-3.27
Properties
0.00
Machinery Furniture Equipment
3.17
Other Properties
8.38
Leases
10.77
Investments And Advances
25.50
Other Non Current Assets
0.19
Total Liabilities Net Minority Interest
26.46
Current Liabilities
14.03
Payables And Accrued Expenses
8.68
Payables
3.24
Accounts Payable
3.24
Current Accrued Expenses
5.44
Pensionand Other Post Retirement Benefit Plans Current
4.50
Current Debt And Capital Lease Obligation
0.85
Current Capital Lease Obligation
0.85
Total Non Current Liabilities Net Minority Interest
12.43
Long Term Debt And Capital Lease Obligation
12.43
Long Term Capital Lease Obligation
12.43
Stockholders Equity
225.69
Common Stock Equity
225.69
Capital Stock
0.00
Common Stock
0.00
Preferred Stock
0.00
Share Issued
51.45
Ordinary Shares Number
51.45
Treasury Shares Number
0.00
Additional Paid In Capital
535.47
Retained Earnings
-310.00
Gains Losses Not Affecting Retained Earnings
0.22
Other Equity Adjustments
0.22
Total Equity Gross Minority Interest
225.69
Total Capitalization
225.69
Working Capital
193.38
Invested Capital
225.69
Total Debt
13.29
Capital Lease Obligations
13.29
Net Tangible Assets
225.69
Tangible Book Value
225.69
Available For Sale Securities
25.50
Investmentin Financial Assets
25.50
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-73.58
-43.48%
-51.28
+7.86%
-55.66
+12.71%
-63.76
Cash Flow From Continuing Operating Activities
-73.58
-43.48%
-51.28
+7.86%
-55.66
+12.71%
-63.76
Net Income From Continuing Operations
-77.74
-32.42%
-58.71
+14.87%
-68.96
+5.94%
-73.32
Depreciation Amortization Depletion
0.13
-88.37%
1.14
-8.99%
1.26
+299.05%
0.32
Depreciation
0.13
-88.37%
1.14
-8.99%
1.26
+299.05%
0.32
Depreciation And Amortization
0.13
-88.37%
1.14
-8.99%
1.26
+299.05%
0.32
Other Non Cash Items
-0.07
+75.34%
-0.29
+21.08%
-0.37
-252.26%
0.24
Stock Based Compensation
5.92
-33.23%
8.87
-28.31%
12.38
+21.38%
10.20
Operating Gains Losses
0.04
-99.21%
4.67
—
—
Gain Loss On Sale Of PPE
0.04
-99.21%
4.67
0.00
0.00
Change In Working Capital
0.91
+157.41%
-1.59
-129.33%
5.43
+1055.46%
-0.57
Change In Prepaid Assets
3.92
+246.60%
-2.67
-255.19%
1.72
+194.20%
-1.83
Change In Payables And Accrued Expense
-3.01
-457.43%
0.84
-70.67%
2.87
+267.86%
-1.71
Change In Accrued Expense
0.42
+116.71%
-2.50
-195.02%
2.63
+299.55%
-1.32
Change In Payable
-3.42
-202.45%
3.34
+1322.13%
0.23
+160.41%
-0.39
Change In Account Payable
-3.42
-202.45%
3.34
+1322.13%
0.23
+160.41%
-0.39
Change In Other Working Capital
—
0.24
-71.21%
0.84
—
Change In Other Current Liabilities
—
0.24
-71.21%
0.84
-71.81%
2.97
Investing Cash Flow
70.17
+31.53%
53.35
+205.55%
-50.55
-3594.81%
-1.37
Cash Flow From Continuing Investing Activities
70.17
+31.53%
53.35
+205.55%
-50.55
-3594.81%
-1.37
Net PPE Purchase And Sale
0.00
+100.50%
-0.40
+58.00%
-0.96
+87.95%
-7.98
Purchase Of PPE
-0.03
+95.57%
-0.66
+31.91%
-0.96
+87.95%
-7.98
Sale Of PPE
0.03
-87.65%
0.25
0.00
0.00
Capital Expenditure
-0.03
+95.57%
-0.66
+31.91%
-0.96
+87.95%
-7.98
Net Investment Purchase And Sale
70.17
+30.53%
53.76
+208.42%
-49.58
-849.44%
6.62
Purchase Of Investment
-88.20
+40.52%
-148.29
+32.76%
-220.54
+3.78%
-229.20
Sale Of Investment
158.37
-21.61%
202.04
+18.18%
170.96
-27.50%
235.81
Financing Cash Flow
0.51
+61.34%
0.31
-99.12%
35.58
+3613.67%
0.96
Cash Flow From Continuing Financing Activities
0.51
+61.34%
0.31
-99.12%
35.58
+3613.67%
0.96
Net Common Stock Issuance
0.00
0.00
-100.00%
35.12
0.00
Proceeds From Stock Option Exercised
0.51
+61.34%
0.31
-31.36%
0.46
-52.40%
0.96
Changes In Cash
-2.90
-221.70%
2.38
+103.37%
-70.62
-10.06%
-64.17
Effect Of Exchange Rate Changes
0.01
+120.00%
-0.04
-202.94%
0.03
0.00
Beginning Cash Position
40.88
+6.09%
38.53
-64.69%
109.12
-37.03%
173.29
End Cash Position
37.98
-7.08%
40.88
+6.09%
38.53
-64.69%
109.12
Free Cash Flow
-73.61
-41.72%
-51.94
+8.27%
-56.62
+21.08%
-71.74
Income Tax Paid Supplemental Data
—
—
0.00
0.00
Amortization Of Securities
-2.77
+48.41%
-5.37
+0.28%
-5.39
-757.64%
-0.63
Common Stock Issuance
0.00
0.00
-100.00%
35.12
0.00
Issuance Of Capital Stock
0.00
0.00
-100.00%
35.12
0.00
Net Preferred Stock Issuance
—
—
—
0.00
Preferred Stock Issuance
—
—
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category